By Katya Svoboda and Alexis Matos Given the difficulty of implementing risk-sharing deals in Europe, should manufacturers in the U.S. even bother setting up these complex arrangements? After all, these innovative contracts, typically tied to a drug’s performance, are notoriously tough to put in place. In many cases the systems required to capture the relevant data are missing, and the lack of coordination between medical and pharmacy benefits means conflicting incentives could be operating within … Continue reading
Building The Greater Real Endpoints Community
You know that old saw “it takes a village”? Before you roll your eyes, consider this: the same underlying premise embodied by this oft-uttered phrase is what’s driving the new openness called “externalization” at drug and device makers. Simply put, in the past few years, product makers have realized that they don’t have a lock on innovation and need to find ways to access new ideas as they reshape their pipelines. So what are … Continue reading